# Discuss methylphenidate for your child Published by Pawel Jozefiak. [About this project](https://adhd100.jock.pl/about/), [How we check sources](https://adhd100.jock.pl/methodology/) - Canonical: https://adhd100.jock.pl/discuss-methylphenidate-child/ - Language: en - First published: 2026-09-29 - Evidence checked: 2026-09-29, using AI-assisted source verification - Clinical review: Not clinically reviewed - Number 1 of 100 in the list: https://adhd100.jock.pl/#discuss-methylphenidate-child This first medication option has strong evidence for reducing ADHD symptoms in school age children. **The number:** Children and teens: medium symptom improvement vs placebo over about 12 weeks (SMD 0.762) ([BMJ / Gosling et al., 2025](https://raw.githubusercontent.com/CorentinJGosling/EBI-ADHD-UR-2025/86eff22a9ffb/datasets/dataset-ur-adhd.csv)) ## The evidence - How sure: Certainty of evidence: High certainty. Measured in people with ADHD. - See this comparison on the evidence map: https://adhd100.jock.pl/evidence/#r-methylphenidate-youth-core-adhd-symptoms-clinician-rated-short - Evidence grade: A. Grade A: moderate or high certainty evidence in people with ADHD, or an explicit ADHD guideline recommendation. - Basis: EBI re-estimation: 6 trials, 1038 children and adolescents, short term; NICE NG87 1.7.7 first-line medicine - Outcome: clinician-rated core ADHD symptom improvement in youth - Comparison: vs placebo - Benefit: 92/100. The benefit score is an editorial prioritization for the general list, weighted by certainty. It is not a prediction of what will happen for you. ## Why it matters Methylphenidate changes brain signalling involved in attention and behaviour. EBI rates the evidence high certainty: clinicians scored symptoms in school age children and adolescents 0.762 SMD better than on placebo, a standardised score gap rather than a percentage. That covers about 12 weeks, or the end of the trial, so lasting benefit is not proven. Cochrane's 2025 review used different methods and rated its evidence very low certainty (teacher-rated SMD 0.74, 21 trials), so the high rating holds for the EBI analysis only. ## How to do it 1. Ask whether methylphenidate, which NICE recommends as the first medicine for children aged 5 and over, fits your child's needs. 2. Bring one or two real examples of what your child wants treatment to help with. 3. Talk through what it should help, the side effects, and how the clinician will check both. 4. Settle how your child, your family and the school will report changes at follow-up. ## Talk to a clinician first Only a qualified prescriber can decide whether methylphenidate suits your child. The estimate is for school age children and does not apply to preschoolers. ## Putting it into practice ### Start now - 1 minute: Type one line in your phone notes: the difficulty your child would want treatment to help with. - 5 minutes: Write down one thing you hope it helps and one worry, to take to the prescriber. - 15 minutes: List the support your child already gets, their health conditions and medicines, and what you want to ask about monitoring. ### What it looks like - A teacher's note on how your child takes part in lessons, plus your child's own goal in their words. - Ask how appetite and sleep will be checked, not only whether symptoms improve. ### Common mistakes - Looking calmer is not the only goal. Talk about how your child joins in and how they feel. - A trial average cannot predict how your child will respond, so agree follow-up for them in particular. ### A structured start **Prepare a medication discussion** 1. Agree the problems treatment should address. 2. Discuss suitability and monitoring with the clinician. 3. Bring feedback from your child and school to the planned review. ### Trusted how-to guides - [Common questions about methylphenidate for children](https://www.nhs.uk/medicines/methylphenidate-children/common-questions-about-methylphenidate-for-children/), NHS - [Tips for Talking With a Health Care Provider About Your Mental Health](https://www.nimh.nih.gov/health/publications/tips-for-talking-with-your-health-care-provider), NIMH ## Sources - [EBI-ADHD: companion data to Gosling et al., BMJ 2025, commit 86eff22a9ffb](https://raw.githubusercontent.com/CorentinJGosling/EBI-ADHD-UR-2025/86eff22a9ffb/datasets/dataset-ur-adhd.csv), BMJ / Gosling et al., 2025 (Tier 1 guideline) - [Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making](https://pmc.ncbi.nlm.nih.gov/articles/PMC12651917/), BMJ, 2025 (Tier 1 guideline) - [Attention deficit hyperactivity disorder: diagnosis and management (NG87), recommendations](https://www.nice.org.uk/guidance/ng87/chapter/Recommendations), NICE, 2019 (Tier 1 guideline) - [Common questions about methylphenidate for children](https://www.nhs.uk/medicines/methylphenidate-children/common-questions-about-methylphenidate-for-children/), NHS, 2025 (Tier 1 guideline) - [Methylphenidate for children and adolescents with attention deficit hyperactivity disorder](https://www.cochrane.org/evidence/CD009885_methylphenidate-effective-treatment-children-and-adolescents-attention-deficit-hyperactivity), Cochrane, 2025 (Tier 1 guideline) --- General information about ADHD, not a diagnosis or an individual treatment plan. Tailoring changes the order of suggestions; it does not assess you. Medication decisions belong with you and a qualified clinician. Report an error: meet@jock.pl Reuse: CC BY 4.0, https://creativecommons.org/licenses/by/4.0/